HPV-related oropharyngeal cancer

+Practice

In print

CLINICAL UPDATE

HPV-related oropharyngeal cancer

21 July 2021

By Ramesh Pandey and Swee Tan

Wednesday 21 July 2021, 12:15 AM

Figure 1. Axial (A) and coronal (B) PET-CT showing HPV-positive oropharyngeal squamous cell carcinoma affecting the left tonsil with metastases in the neck

World Head and Neck Cancer Day on 27 July is an opportunity to remind all healthcare providers to take part in education, early diagnosis and prevention of human papillomavirus-related oropharyngeal cancer

Ramesh Pandey and Swee Tan

This article has been endorsed by the RNZCGP and has been approved for up to 0.25 CME credits for the General Practice Educational Programme and conti, Educate small, BACK panel - grey

Oncology

Vaccines

References

Elwood JM, Youlden DR, Chelimo C, et al. Comparison of oropharyngeal and oral cavity squamous cell cancer incidence and trends in New Zealand and Queensland, Australia. Cancer Epidemiol 2014:38:16–21.

Chelimo C, Elwood JM. Sociodemographic differences in the incidence of oropharyngeal and oral cavity squamous cell cancers in New Zealand. ANZ J Public Health 2015;39(2):162–67.

Kwon HJ, Brasch HD, Benison S, et al. Changing prevalence and treatment outcomes of patients with p16 human papillomavirus related oropharyngeal squamous cell carcinoma in New Zealand. Br J Oral Maxillofac Surg 2016;54(8):898–903.

Hong AM, Grulich AE, Jones D, et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 2010;28:3269–72.

Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus (HPV) and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294–301 .

Näsman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009:125:362–66.

Petousis-Harris H, Alley L. Human Papillomavirus Vaccination: Hesitancy and Uptake. Research Review; 2019. https://bit.ly/3x8i6V3

Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. Natl Cancer Inst 2000;92:709–20.

Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333(6046):1157–60.

Ministry of Health. Immunisation Handbook 2020: Human papillomavirus. https://www.health.govt.nz/our-work/immunisation-handbook-2020/10-human-papillomavirus

Professional Advisory Board of the Sexually Transmitted Infections Education Foundation. Guidelines for the Management of Genital, Anal and Throat HPV Infection in New Zealand, 9th edition. Auckland, NZ: Sexually Transmitted Infections Education Foundation; 2017. https://bit.ly/3qAWzlp

Kumar V, Abbas A, Aster J. Neoplasia. Robbins and Cotran Pathologic Basis of Disease, 9th edition (pp. 326-27). Elsevier; 2015.

Lucas-Roxburgh R, Benschop J, Lockett B, et al. The prevalence of human papillomavirus in oropharyngeal cancer in a New Zealand population. PLoS ONE 2017;12(10):e0186424.

Merck. FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers. 12 June 2020. https://bit.ly/3AqyrXc

Australian Government Department of Health. www.health.gov.au

Practice archive

How to Treat

+How to treat

Heart failure

Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality

Wednesday 29 January 2025, 12:45 AM